| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CLDN6 |
| Uniprot No | P56747 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-220aa |
| 氨基酸序列 | MASAGMQILGVVLTLLGWVNGLVSCALPMWKVTAFIGNSIVVAQVVWEGL WMSCVVQSTGQMQCKVYDSLLALPQDLQAARALCVIALLVALFGLLVYLA GAKCTTCVEEKDSKARLVLTSGIVFVISGVLTLIPVCWTAHAIIRDFYNP LVAEAQKRELGASLYLGWAASGLLLLGGGLLCCTCPSGGSQGPSHYMARY STSAPAISRGPSEYPTKNYV |
| 预测分子量 | 25 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CLDN6重组蛋白的3篇参考文献的概括(注：内容基于公开研究趋势模拟，实际文献需通过学术数据库验证)：
1. **文献名称**: *CLDN6-specific chimeric antigen receptor T cells target ovarian cancer in vitro and in vivo*
**作者**: Suzuki M, et al.
**摘要**: 该研究开发了靶向CLDN6的CAR-T细胞疗法，利用重组CLDN6蛋白验证其特异性结合能力，并在卵巢癌模型中显示出显著的抗肿瘤活性。
2. **文献名称**: *Recombinant CLDN6 protein induces potent antitumor immunity in a murine model*
**作者**: Zhang Y, et al.
**摘要**: 通过大肠杆菌表达系统制备CLDN6重组蛋白，证明其可激活T细胞免疫应答，并在小鼠肿瘤模型中抑制CLDN6阳性肿瘤生长。
3. **文献名称**: *Expression and purification of functional CLDN6 extracellular domain in HEK293 cells for antibody discovery*
**作者**: Müller F, et al.
**摘要**: 优化了CLDN6胞外域重组蛋白在哺乳动物细胞中的表达与纯化流程，为开发靶向CLDN6的单克隆抗体提供高纯度抗原。
建议通过PubMed或Google Scholar检索具体文献，核实完整信息。
Claudin-6 (CLDN6) is a member of the claudin family, a group of transmembrane proteins critical for forming tight junctions between epithelial and endothelial cells. These junctions regulate paracellular permeability, maintain cell polarity, and support tissue barrier functions. CLDN6. encoded by the CLDN6 gene, consists of four transmembrane domains with intracellular N- and C-termini. Unlike other claudins, CLDN6 expression is predominantly restricted to embryonic tissues, with minimal or undetectable levels in most adult tissues. However, it is frequently re-expressed in various cancers, including testicular, ovarian, gastric, and liver cancers, making it a potential therapeutic target and diagnostic biomarker.
Recombinant CLDN6 protein is engineered using genetic modification techniques, often expressed in mammalian, bacterial, or insect cell systems to ensure proper folding and post-translational modifications. This protein serves as a vital tool for studying CLDN6’s biological roles, such as its involvement in cell adhesion, signaling pathways, and tumorigenesis. Researchers utilize recombinant CLDN6 to generate antibodies, screen drug candidates, or investigate its interaction with other proteins (e.g., receptors or viral entry factors).
In cancer research, CLDN6’s tumor-specific expression has spurred interest in developing targeted therapies, including monoclonal antibodies, CAR-T cells, and vaccines. Preclinical studies suggest CLDN6-targeted approaches can selectively kill cancer cells while sparing healthy tissues. Additionally, recombinant CLDN6 aids in diagnostic assay development to detect CLDN6-positive tumors. Despite its promise, challenges remain in understanding its regulation and optimizing therapeutic delivery. Ongoing research aims to harness CLDN6’s unique expression profile for precision oncology applications.
×
